DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

Tsagiopoulou, Maria; Papakonstantinou, Nikos; Moysiadis, Theodoros; Mansouri, Larry; Ljungström, Viktor; Duran-Ferrer, Martí; Malousi, Andigoni; Queirós, Ana C.; Plevova, Karla; Bhoi, Sujata; Kollia, Panagoula; Oscier, David; Anagnostopoulos, Achilles; Trentin, Livio; Ritgen, Matthias; Pospisilova, Sarka; Stavroyianni, Niki; Ghia, Paolo; Martin-Subero, Jose I.; Pott, Christiane; Rosenquist, Richard; Stamatopoulos, Kostas

doi:10.1186/s13148-019-0783-1

Clinical Epigenetics

Table 1 Clinical data and results of the intra-individual DNA methylation analysis

From: DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

Patient ID	U-CLL	IGHV gene	Age at diagnosis	First-line treatment	Treatment response	TTFT	TTR	Cytogenetic alterations*	Pearson R (MBC vs pre-treatment)	Epigenetic burden	Pearson R (pre-treatment vs relapse)	Relapse changes
P1	NO	IGHV3-11	48	FCR	PR	1.6	4.7	None	0.93	32,380	0.99	117
P2	ND	IGHV1-f	61	FCR	CR	1.1	2.6	del(13q)	0.92	33,441	0.96	20,440
P3	YES	IGHV3-33	55	FCR	CR	0.1	2.3	None	0.93	34,285	0.82	81,383
P4	YES	IGHV1-69	60	FCR	CR	4.3	5.5	Trisomy 12	0.93	35,098	0.98	8052
P5	YES	IGVH1-69	60	FCR	PR	1.4	1.4	del(13q)	0.92	36,696	0.98	3430
P6	YES	IGHV3-33	52	FCR	CR	4.1	6.4	del(13q)	0.92	37,146	0.99	3441
P7	YES	IGHV4-39	62	FCR	CR	2.2	3.6	del(11q), del(13q)	0.92	37,465	0.89	58,299
P8	YES	IGHV1-69	46	FCR	PR	0.3	1.7	del(11q)	0.92	38,023	0.99	1514
P9	YES	IGHV4-31	64	FCR	CR	4.1	3.8	None	0.91	38,652	0.92	40,706
P10	YES	IGHV1-69	61	FCR	CR	1.2	2.2	del(11q)	0.91	39,164	0.97	8199
P11	YES	ND	56	BR	CR	2	3.9	del(13q)	0.92	39,658	1.00	45
P12	YES	IGHV5-a	73	FCR	CR	0.2	3.8	ND	0.92	40,403	0.87	60,970
P13	YES	IGHV3-20	49	FCΜR	PR	2.5	4.1	Trisomy 12	0.91	40,669	0.99	511
P14	YES	ND	29	FCR	PR	1.5	4.8	del(11q), del(13q)	0.91	40,755	0.99	1263
P15	YES	IGHV1-69	66	FCR	CR	3.4	0.9	del(11q), del(13q)	0.91	41,333	0.99	261
P16	YES	IGHV4-34	44	FCR	CR	2.7	1.4	del(11q)	0.91	41,399	0.99	392
P17	YES	ND	36	FCR	CR	2.2	5.0	None	0.90	41,875	0.98	3150
P18	YES	IGHV3-64	26	FCR	CR	0.9	1.3	del(17p)	0.91	42,313	0.99	949
P19	NO	IGHV1-69	48	FCR	CR	6.1	1.8	del(13q)	0.92	42,384	1.00	45
P20	YES	IGHV1-69	61	FCR	ND	0	1.1	del(6q)	0.91	42,543	0.99	457
P21	YES	IGHV1-24	59	FCR	CR	0	1.2	None	0.91	42,615	0.99	907
P22	YES	IGHV3-30	56	FCR	CR	0	0.8	del(11q)	0.91	42,721	0.99	287
P23	YES	IGHV1-69	54	FCR	CR	1.5	0.9	del(11q), del(13q)	0.90	44,283	0.99	90
P24	NO	IGHV1-69	ND	FCR	CR	4.7	1.2	del(11q , del(13q)	0.91	45,253	1.00	45
P25	YES	IGHV3-48	65	FCR	CR	2	8.0	del(13q)	0.91	45,372	0.99	905
P26	YES	IGHV1-69	64	FCR	CR	0.1	2.2	del(11q)	0.89	45,383	0.98	4689
P27	ND	IGHV3-53	43	FCR	CR	0.1	10.9	Trisomy 12	0.89	45,999	0.96	10,449
P28	YES	IGVH3B	61	FCR	CR	0.1	1.4	del(17p)	0.90	46,314	0.89	51,925
P29	YES	IGHV4-34	53	FCR	CR	0	7.9	None	0.90	50,072	0.98	8546
P30	YES	ND	55	FC	CR	2	3.0	del(11q)	0.89	50,443	0.98	2740
P31	YES	IGVH3B	50	FCR	CR	0.1	1.5	del(13q)	0.89	52,336	1.00	57
P32	YES	IGHV3-48	70	FCR	CR	0.2	5.1	del(11q)	0.89	53,793	0.98	4504
P33	YES	IGVH3A-3B	59	FCR	CR	0	2.1	del(6q)	0.86	59,041	0.97	6584
P34	YES	IGHV1-3	38	FCR	PR	1	3.0	del(13q)	0.89	60,526	0.98	2985

TTFT time to first treatment (years) TTR time to relapse (years), ND not determined. *Detected by karyotype and/or FISH (pre-treatment state)

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com